Measurement of anti-Xa activity of apixaban in plasma

被引：0
|
作者：
Samama, M. M. [1 ]
Guinet, C. [1 ]
Le Flem, L. [1 ]
Amiral, J. [2 ]
机构：
[1] Biomnis Lab, Ivry, France
[2] Hyphen BioMed, Neuville Sur Oise, France
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2013年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：826 / 827
页数：2
相关论文
共 50 条
  • [21] Assessment of apixaban on automated analyzers using a Liquid Anti-Xa assay
    Cao, Z.
    Kung, C.
    Bottenus, R.
    Triscott, M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 951 - 952
  • [22] ANTI-XA ASSAY FOR MEASUREMENT OF PLASMA RIVAROXABAN IS NOT AFFECTED BY THE ADDITION OF EXOGENOUS ANTITHROMBIN
    Bozic-Mijovski, M.
    Malovrh, P.
    [J]. THROMBOSIS RESEARCH, 2014, 133 : S85 - S86
  • [23] Utilization of apixaban anti-Xa levels in transition from apixaban to warfarin in a patient with chronic renal dysfunction
    Elgersma, Brittany
    Zochert, Sara
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (09) : E104 - E109
  • [24] UTILITY OF APIXABAN OR RIVAROXABAN ANTI-XA LEVELS IN TRANSITIONING PATIENTS TO HEPARIN INFUSIONS
    Huang, Wan-Ting
    Nguyen, Kevin
    Patel, Aakash
    Lerner, Dmitri
    [J]. CRITICAL CARE MEDICINE, 2022, 50 (01) : 447 - 447
  • [25] Does in vitro hemolysis affect measurements of plasma apixaban concentration by UPLC-MS and anti-Xa assay?
    Roed-Undlien, Henriette
    Schultz, Nina Haagenrud
    Amundsen, Erik Koldberg
    Wollmann, Birgit M.
    Molden, Espen
    Akerkar, Rupali R.
    Bjornstad, Johannes Lagethon
    [J]. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2024,
  • [26] Anti-Xa activity in patients with hepatocellular carcinoma
    Triantos, Christos
    Emmanuil, Andreas
    Aggeletopoulou, Ioanna
    Tsolias, Chrysostomos
    Grigoropoulou, Xristina
    Jelastopulu, Eleni
    Koukias, Nikolaos
    Assimakopoulos, Stelios
    Gogos, Charalambos
    Labropoulou-Karatza, Chrisoula
    Thomopoulos, Konstantinos
    [J]. JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2017, 26 (01) : 91 - 92
  • [27] THE EFFECTS OF POST-HEPARIN PLASMA LIPASES ON ANTI-XA CLOTTING ACTIVITY
    WILLIAMS, SP
    BARROWCLIFFE, TW
    [J]. THROMBOSIS RESEARCH, 1985, 37 (03) : 371 - 377
  • [28] Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels
    Boissier, Elodie
    Senage, Thomas
    Babuty, Antoine
    Gouin-Thibault, Isabelle
    Rozec, Bertrand
    Roussel, Jean-Christian
    Sigaud, Marianne
    Ternisien, Catherine
    Trossaert, Marc
    Fouassier, Marc
    Lakhal, Karim
    [J]. ANESTHESIA AND ANALGESIA, 2021, 132 (03): : 707 - 716
  • [29] Apixaban Exposure and Anti-Xa Activity in Nonvalvular Atrial Fibrillation Patients: An Application of Population PK/PD Analysis
    Kowalsk, Ken
    Nielsen, Jace
    Roy, Amit
    Thanneer, Neelima
    Byon, Wonkyung
    Boyd, Rebecca
    Wang, Xiaoli
    Leil, Tarek
    LaCreta, Frank
    Frost, Charles
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S19 - S20
  • [30] Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins
    Milner, Erin
    Ainsworth, Michael
    Gleaton, Melinda
    Bookstaver, David
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (05) : 668 - 675
12345